Mitsubishi Tanabe’s Oral Edaravone Accepted for Swiss Review in ALS

Mitsubishi Tanabe Pharma said on April 25 that an oral suspension version of its ALS therapy Radicava (edaravone) has been accepted by Swiss regulatory authorities for review. The drug is currently available in IV formulations. The company’s German-based subsidiary had...read more